Both pathways promote angiogenesis by regulating VEGF expression [30] By inhibiting these pathways, the combination therapy decreases VEGF production, impairs endothelial cell functions, and disrupts angiogenesis, thereby altering the tumor microenvironment and limiting tumor growth and metastasis. This evidence concerns the gene VEGFA and neoplasm.